Compare Cadila Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs VENUS REMEDIES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE VENUS REMEDIES CADILA HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x 31.8 -5.0 - View Chart
P/BV x 3.8 0.3 1,131.5% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 CADILA HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
VENUS REMEDIES
Mar-18
CADILA HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs432126 343.4%   
Low Rs30661 501.5%   
Sales per share (Unadj.) Rs128.6301.8 42.6%  
Earnings per share (Unadj.) Rs18.5-24.9 -74.6%  
Cash flow per share (Unadj.) Rs24.42.5 958.7%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs101.5293.3 34.6%  
Shares outstanding (eoy) m1,023.7412.34 8,296.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.90.3 927.1%   
Avg P/E ratio x19.9-3.8 -529.8%  
P/CF ratio (eoy) x15.136.7 41.2%  
Price / Book Value ratio x3.60.3 1,142.1%  
Dividend payout %18.90-   
Avg Mkt Cap Rs m378,1701,154 32,776.3%   
No. of employees `00012.40.9 1,344.6%   
Total wages/salary Rs m21,241393 5,403.5%   
Avg. sales/employee Rs Th10,585.04,026.1 262.9%   
Avg. wages/employee Rs Th1,707.8425.0 401.8%   
Avg. net profit/employee Rs Th1,526.5-331.8 -460.1%   
INCOME DATA
Net Sales Rs m131,6563,724 3,535.2%  
Other income Rs m2,01123 8,937.8%   
Total revenues Rs m133,6673,747 3,567.7%   
Gross profit Rs m29,731395 7,530.6%  
Depreciation Rs m5,986338 1,769.4%   
Interest Rs m1,935354 546.1%   
Profit before tax Rs m23,821-275 -8,652.7%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,30332 16,781.6%   
Profit after tax Rs m18,987-307 -6,186.7%  
Gross profit margin %22.610.6 213.0%  
Effective tax rate %22.3-11.5 -193.9%   
Net profit margin %14.4-8.2 -175.0%  
BALANCE SHEET DATA
Current assets Rs m84,9812,638 3,221.8%   
Current liabilities Rs m73,4252,305 3,186.0%   
Net working cap to sales %8.88.9 98.2%  
Current ratio x1.21.1 101.1%  
Inventory Days Days75135 55.0%  
Debtors Days Days11046 236.4%  
Net fixed assets Rs m133,4934,871 2,740.7%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m102,8393,496 2,941.9%   
Net worth Rs m103,8633,619 2,869.9%   
Long term debt Rs m39,4971,374 2,873.8%   
Total assets Rs m234,8317,509 3,127.5%  
Interest coverage x13.30.2 5,969.5%   
Debt to equity ratio x0.40.4 100.1%  
Sales to assets ratio x0.60.5 113.0%   
Return on assets %8.90.6 1,411.3%  
Return on equity %18.3-8.5 -215.6%  
Return on capital %18.31.6 1,156.3%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m48,4040-   
Fx outflow Rs m11,593517 2,244.5%   
Net fx Rs m36,811-517 -7,127.0%   
CASH FLOW
From Operations Rs m28,823514 5,603.2%  
From Investments Rs m-57,387-123 46,618.2%  
From Financial Activity Rs m18,846-387 -4,868.5%  
Net Cashflow Rs m-7,1054 -169,166.7%  

Share Holding

Indian Promoters % 74.8 32.9 227.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,611.1%  
FIIs % 5.9 0.6 1,017.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 66.4 16.6%  
Shareholders   44,069 20,121 219.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades Flat, GAIL Q1 Results, Falling Gold Prices, and Top Buzzing Stocks Today(Pre-Open)

Indian share markets ended marginally lower for the second consecutive day yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 59 points.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

3 Stocks to Ride the Big Rebound in Smallcaps(Profit Hunter)

Aug 11, 2020

The rebound ratio suggests that smallcaps are set for big gains but this time it will be limited to a few stocks. Make sure you choose wisely.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 13, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS